Latest News
Merck reports positive Phase 3 data for investigational two-drug HIV regimen doravirine/islatravir
15 October 2025 - Biopharmaceutical company Merck (NYSE: MRK), known as MSD outside the US and Canada, reported on Wednesday that it has presented new data from two Phase 3 studies evaluating its investigational, once-daily oral two-drug HIV regimen,...
Novocure announces presentation of new TTFields research at EANO and ESMO 2025 meetings
15 October 2025 - Oncology company Novocure (NASDAQ: NVCR) announced on Wednesday that it will present new data on its Tumor Treating Fields (TTFields) therapy at the 2025 European Association of Neuro-Oncology (EANO) Meeting in Prague, Czech Republi...
Merck KGaA to acquire JSR Life Sciences chromatography business to expand Protein A capabilities
15 October 2025 - German science and technology company Merck KGaA (ETR:MRK) announced on Wednesday that its Life Science business, which operates as MilliporeSigma in the US and Canada, has signed a definitive agreement to acquire the chromatography...
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study
15 October 2025 - US-based pharmaceutical company 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW), a developer of medicines for vector-borne disease, said on Wednesday that the first patient to complete its expanded access trial of tafenoquine...
Minovia Therapeutics' MNV-201 receives FDA Orphan Drug Designation for Myelodysplastic Syndrome
15 October 2025 - Minovia Therapeutics Ltd., an Israeli clinical-stage biotechnology company, announced on Wednesday that the US Food and Drug Administration has granted Orphan Drug Designation for its lead investigational compound MNV-201 for myelod...